Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Warner Chilcott PLC (WCRX)

  Print      Mail a friend

Monday 23 August, 2004

Warner Chilcott PLC

Regulatory Approval

Warner Chilcott PLC
23 August 2004

Craigavon, Northern Ireland/Rockaway, NJ                          23 August 2004

                                Warner Chilcott PLC

                        Announces approval of FemtraceTM

Craigavon, Northern Ireland/Rockaway, New Jersey, USA - 23 August 2004: Warner
Chilcott PLC ('Warner Chilcott') (LSE: WCRX, Nasdaq: WCRX), announced today that
the US Food & Drug Administration (FDA) has approved FemtraceTM tablets for the
relief of the vasomotor symptoms of menopause.  An approval was not granted for
the secondary indication of vulvar-vaginal atrophy. The New Drug Application
(NDA) for FemtraceTM was accepted for filing on December 19, 2003.  All dosage
strengths, i.e. 0.45 mg, 0.9 mg and 1.8 mg of estradiol acetate were approved.
The Company expects to launch FemtraceTM in the first quarter of 2005.

FemtraceTM is the first approval of three applications currently filed with the
FDA.  Approvals for femhrt(R)Lo, a low-dose version of femhrt(R), a combined
oral estrogen-progestogen product, and a line extension to Doryx(R), a
tetracycline antibiotic for the treatment of acne, are expected in the first
half of next year.

Warner Chilcott also confirms today that, following recent meetings with LEO
Pharma S/A (LEO), it is expected that an NDA for Dovobet(R), a combination of
calcipotriene and betamethasone dipropionate, will be filed by March 2005.
Dovobet(R) is indicated for the treatment of psoriasis.  Under the terms of a
Master Agreement dated April 1, 2003, Warner Chilcott has agreed to license
Dovobet(R) from LEO upon marketing approval of the product for the US market.
Dovobet(R) has been approved and is currently marketed in at least 23 countries

The Company has decided to discontinue its programmes to develop a metronidazole
vaginal ring to treat bacterial vaginosis and a fluconazole vaginal ring for

Commenting on today's news, Roger Boissonneault, CEO of Warner Chilcott, said:

'We welcome the approval of FemtraceTM.  This is the first of a series of new
products either currently filed with the FDA or due to be submitted in 2005.
These products will help strengthen our presence in women's healthcare and
dermatology and will drive future growth of Warner Chilcott past the end of this
decade.  My congratulations go to all those colleagues who contributed to this
important project.'

                                    - END -

For further information, please contact:

Warner Chilcott PLC
David G. Kelly                              Tel:     + 44 (0) 28 3836 3634

Financial Dynamics
Sophie Pender-Cudlip/Lucy Briggs            Tel:     + 44 (0) 20 7831 3113

For further information on Warner Chilcott visit:


Forward looking statements in this report, including, without limitation,
statements relating to Warner Chilcott's plans, strategies, objectives,
expectations, intentions and adequacy of resources, are made pursuant to the
safe harbor provisions of the U.S. Private Securities Litigation Reform Act of
1995.  These forward looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of Warner Chilcott to be materially different from any future
results, performance or achievements expressed or implied by such forward
looking statements.  These factors include, among others, the following: Warner
Chilcott's ability to manage its growth, government regulation affecting the
development, manufacture, marketing and sale of pharmaceutical products,
customer acceptance of new products, competitive factors in the industries in
which Warner Chilcott operates, the loss of key senior management or scientific
staff, exchange rate fluctuations, general economic and business conditions, and
other factors described in filings of Warner Chilcott  with the SEC.  Warner
Chilcott undertakes no obligation to publicly update or revise any forward
looking statement, whether as a result of new information, future events or

                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                                                    

a d v e r t i s e m e n t